<DOC>
	<DOCNO>NCT00062023</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . It yet know whether sulindac , aspirin , ursodiol effective preventing colorectal cancer . PURPOSE : This randomized phase II trial study well sulindac work compare aspirin ursodiol prevent colorectal cancer .</brief_summary>
	<brief_title>Comparison Sulindac , Aspirin , Ursodiol Preventing Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine percentage change colorectal aberrant crypt focus ( ACF ) patient history colorectal cancer high risk colorectal cancer treat sulindac v aspirin v ursodiol . - Determine safety efficacy drug , term ability cause regression exist colorectal ACF prevent new ACF development , patient . OUTLINE : This partially blind , randomize , placebo-controlled study . Patients stratify accord colorectal neoplasia ( adenoma v carcinoma ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral sulindac twice daily . - Arm II : Patients receive oral aspirin daily . - Arm III : Patients receive oral ursodiol three time daily . - Arm IV : Patients receive oral sulindac placebo twice daily . In arm , treatment continue 12 month absence disease progression unacceptable toxicity . Patients undergo colonoscopy baseline end treatment . Patients follow 2 month end treatment . PROJECTED ACCRUAL : A total 172 patient ( 43 per treatment arm ) history colorectal cancer adenoma accrue study . A total 20 additional patient elevate risk colorectal neoplasia accrue , randomize , study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . Male female subject , age 4080 year 2. &gt; 5 colorectal ACF prior history colorectal cancer define Dukes A/B1 carcinoma within 5 year entry stage colorectal cancer least 5 year post surgical resection ( 86 subject ) 3. &gt; 5 colorectal ACF recent/current history colorectal adenoma ( ) define one following : one adenomatous polyp &gt; 1cm two adenomatous polyp size one adenomatous polyp size document history adenomatous polyp ( ) ( 86 subject ) 4 . No elevated risk colorectal cancer adenoma ( 20 subject ) 5 . Subjects permit use Nasonex nasal steroid prohibit . Subjects may change Nasonex must discontinue previous nasal steroid use least 30 day prior study randomization . 6 . If participant female childbearing potential , must agree use adequate contraception must negative serum pregnancy test within 14 day prior study drug administration 7 . No use investigational agent ( ) within last 3 month discretion medical monitor 8 . The subject allow proceed randomization long follow laboratory criterion meet baseline evaluation : Hgb &gt; 10.0 g/dl , platelet count &gt; 100,000/ul ; WBC &gt; 3,000/ul ; ALT &lt; 2 x upper limit normal ; AST &lt; 2 x upper limit normal , total bilirubin &lt; 1.5mg/100ml . 9 . Patients require use hormone modulators Tamoxifen Arimidex permit enroll provide meet eligibility criterion note 1 . Known diagnosis FAP , hereditary nonpolyposis colon cancer ( HNPCC ) , inflammatory bowel disease 2 . History hypersensitivity COX2 inhibitor , sulfonamide , NSAIDs , salicylates , ursodeoxycholic acid 3 . Use NSAIDs , include aspirin , dose six month prior study entry require three month washout period prior eligibility begin time last dose . Participants must NSAIDs three month prior study entry . Individuals cardioprotectant aspirin dose eligible . 4 . History gastroduodenal ulcer document endoscopically would preclude patient participation trial 5 . Known inability participate schedule followup test . 6 . Significant medical psychiatric problem would make patient poor protocol candidate , opinion principal investigator . 7 . `` Unacceptable clinical risk '' proceed ( base upon subclinical discovery make via baseline colonoscopy biopsy ) . 8 . Patient undergone total colectomy 9 . Patient receive chemotherapy within past 6 month randomization study . Topical chemotherapy assess casebycase basis . Any history pelvic rectal radiation therapy exclude patient participate . 10 . History invasive carcinoma past five year ( except patient Dukes A/B1 carcinoma within 5 year entry stage colorectal cancer least 5 year post surgical resection ) 11 . Patients rectal cancer exclude except transanal excision without radiation . 12 . Patients acute liver disease , unexplained transaminase elevation history renal stone would exclude . 13 . Participants permit randomized trial follow laboratory value report baseline : Hgb &lt; 10.0 g/dl , platelet count &lt; 100,000/ul ; WBC &lt; 3,000/ul ; ALT &gt; 2 x upper limit normal ; AST &gt; 2 x upper limit normal , total bilirubin &gt; 1.5mg/100ml .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
</DOC>